Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANECO study of ribavirin-related hemoglobin decline and sustained virologic response in chronic hepatitis C
2011-001256-10Phase 4Completed
- Sponsor
- Roche
- Start
- May 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ribavirin in hepatitis C virus infection, sponsored by Roche. Primary endpoint: Correlation between hemoglobin decline at week 12 and sustained virologic response. Started May 2011; status: completed.
02
Drugs
ribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2011-001256-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001256-10.